

Cardiovascular Measure Endorsement Project 2014 Standing Committee Meeting December 4-5, 2014

National Quality Forum Executive Building 1030 15th Street, NW, Suite 900 Washington, DC 20005 (202) 783-1300

Please use the following information to access the conference call line and webinar:

Day1:

Speaker dial-in #: 1-888-802-7237 Public dial-in #: 1-877-303-9138 Confirmation Code Day #1: 30876317 Weblink Day #1: http://nqf.commpartners.com/se/NQFLogin/673198

Day2:

Speaker dial-in #: 1-888-802-7237 Public dial-in #: 1-877-303-9138 Confirmation Code Day #2: 30876322 Weblink Day #2: http://nqf.commpartners.com/se/NQFLogin/778206

AGENDA

Day 1: December 4, 2014

8:30 am	Continental Breakfast
9:00 am	Welcome Wunmi Isijola, MPH, Project Manager Sharon Hibay, RN, DNP, Senior Director Reva Winkler, MD, MPH, Senior Director Helen Burstin, MD, MPH, Chief Scientific Officer
9:05 am	Introductions and Disclosure of Interest Ann Hammersmith, JD, General Counsel
9:15 am	Portfolio Overview Sharon Hibay, RN, DNP, Senior Director

9:30 am	Updates to Process for Measure Evaluation and Voting <i>Reva Winkler, MD, MPH, Senior Director</i>
9:45 am	 Consideration of Candidate Measures Mary George, MD, MSPH, FACS, FAHA (co-chair) Thomas Kottke, MD, MSPH (co-chair) 0543: Coronary Artery Disease and Medication Possession Ratio for Statin Therapy (CMS)
10:45 am	Break
11:00 am	 Consideration of Candidate Measures (Continued) 0670: Cardiac stress imaging not meeting appropriate use criteria: Preoperative evaluation in low risk surgery patients (ACC) 0671: Cardiac stress imaging not meeting appropriate use criteria: Routine testing after percutaneous coronary intervention (ACC) 0672: Cardiac stress imaging not meeting appropriate use criteria: Testing in asymptomatic, low risk patients (ACC)
12:30 pm	Lunch
1:00 pm	 Consideration of Candidate Measures (Continued) 0090: Electrocardiogram Performed for Non-Traumatic Chest Pain (AMA-PCPI) 1524: Assessment of Thromboembolic Risk Factors (CHADS2) (ACC) 1525: Chronic Anticoagulation Therapy(ACC)
2:45 pm	Break
3:00 pm	 Consideration of Candidate Measures (Continued) 2461: In-person evaluation following implantation of a cardiovascular implantable electronic device (CIED) (HRS) 2474: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation (HRS) 0715: Standardized adverse event ratio for children and adults undergoing cardiac catheterization for congenital heart disease (Children's Hospital Boston)
4:45 pm	NQF Member and Public Comment
5:00 pm	Adjourn

Day 2: December 5, 2014

8:30 am Continental Breakfast

9:00 am Welcome, Recap of Day 1 Mary George, MD, MSPH, FACS, FAHA (co-chair) Thomas Kottke, MD, MSPH (co-chair)

9:05 am	Consideration of Candidate Measures (Continued)	
	• 2438 : Beta-Blocker Therapy (i.e., Bisoprolol, Carvedilol, or Sustained-Release	
	Metoprolol Succinate) for LVSD Prescribed at Discharge (The Joint Commission)	
	• 2439: Post-Discharge Appointment for Heart Failure Patients	
	The Joint Commission)	
	• 2443: Post-Discharge Evaluation for Heart Failure Patients (The Joint Commission)	
10:45 am	Break	
11:00 am	Consideration of Candidate Measures (Continued)	
	• 2440: Care Transition Record Transmitted (The Joint Commission)	
	• 2441: Discussion of Advance Directives/Advance Care Planning (The Joint Commission)	
	• 2442: Advance Directive Executed (The Joint Commission)	
12:15 pm	NQF Member and Public Comment	
-		
12:30 pm	Next Steps Wunmi Isijola, MPH, Project Manager	
12:35 pm	Lunch /Adjourn	